RxDoctor Payments Data

James Black, MD

Cardiovascular Disease · Austin, TXNPI 1831159789

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,585 of the $3,285 with a category attached, or 78.7%. Medtronic accounts for 80.2% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $1,644 and has fallen 89.1% since, to $180 in 2022. That places this record below the midpoint for cardiovascular disease clinicians in TX, where the typical reported total is $3,258.

$3,285in general payments, 2019–2025

Across 22 payments — averaging $149.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Abbott$449
  • Boston Scientific$129
  • Heartflow, Inc.$50
  • E.r. Squibb & Sons, L.L.C.$22
$710in research payments, 2019–2025

Across 2 payments — averaging $355.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$710

What the payments were for

  • Travel & lodging$2,58579%
  • Food & beverage$70021%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,285 in reported general payments places this provider in the 50th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$81,539
Medicare patients
238
Services billed
1,144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban191$200,901
XareltoRivaroxaban57$71,041
MultaqDronedarone Hcl40$46,576
Repatha SureclickEvolocumab18$27,892
EntrestoSacubitril/Valsartan19$17,840
CorlanorIvabradine Hcl12$6,972
Metoprolol Succinate269$3,785
Flecainide Acetate77$2,824
Losartan Potassium74$922
Diltiazem 24hr Er (Cd)Diltiazem Hcl38$860
Rosuvastatin Calcium93$758
Diltiazem 24hr Er (Xr)Diltiazem Hcl13$655
SotalolSotalol Hcl36$604
Ramelteon12$457
Lisinopril55$452

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →